SynthesisFrontiers in oncology2026
Gastric cancer prevention by
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Currently, existing studies lack specific long-term follow-up subgroup analyses for the Chinese population and fail to clarify how sample size and recruitment strategies affect the heterogeneous efficacy of Hp eradication. We therefore integrated data from Hp eradication therapy studies in Chinese Hp-positive patients with ≥3 years of follow-up, quantitatively analyzed the therapy's impact on gastric cancer risk, and explored preventive effect differences across subgroups with varying sample sizes. This study aims to provide evidence-based support for clinical decision-making in gastric cancer primary prevention and the formulation of public health strategies. Methods: We searched six major databases: PubMed, Embase, the Cochrane Library, Web of Science, Wanfang Database, and CNKI (China National Knowledge Infrastructure). The search included all relevant randomized controlled trials (RCTs) from each database's inception to December 31, 2025. After screening based on inclusion and exclusion criteria, we used RevMan 5.3 software for risk of bias assessment, effect size pooling, and subgroup analysis. We assessed evidence quality using the GRADE approach. Results: A total of 8 high-quality randomized controlled trials (RCTs) were included, with 260,609 participants (118,425 receiving Helicobacter pylori [Hp] eradication therapy). Pooled analysis showed that Hp eradication therapy significantly reduced gastric cancer risk by 18% (RR = 0.82, 95%CI: 0.73-0.91, P = 0.0004). Sample size subgroup analysis revealed that the conventional sample mixed group had a 45% lower gastric cancer risk (RR = 0.55), significantly outperforming the ultra-large sample community group (RR = 0.88). For follow-up duration, the subgroup with ≥10 years of follow-up showed a 47% reduction in gastric cancer risk (RR = 0.53, P<0.0001), while short-term intervention (≤5 years) showed a trend toward reduced risk without reaching statistical significance. Conclusion: Helicobacter pylori (Hp) eradication therapy significantly reduces gastric cancer risk in Chinese Hp-positive individuals. It yields more pronounced benefits when participants are recruited via small- and medium-sized community screening or clinical channels, with clear gains observed in long-term follow-up (≥10 years). We recommend promoting this therapy among clinical high-risk populations and in precise community screening to enhance intervention cost-effectiveness. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD420261277174, identifier CRD420261277174.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.